MarketCapExport financials
Becton, Dickinson and Company (BDX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Becton, Dickinson and Company BDX
$ 182.75
1.44%
Facebook
X
Telegram
Becton, Dickinson and Company Financial Ratios 2025-2006 | BDX
Brief overview of Becton, Dickinson and Company's multiples and efficiency
This overview follows the five latest available observations from 2021 through 2025.
Market valuation is represented by P/E 33.47x (median 37.61x), EV/EBITDA 11.01x (median 13.64x), P/S 2.57x (median 3.49x). Valuation is roughly 19.3% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.
At the current P/E, inverse earnings yield is 3%, a useful bridge between price and business earnings.
End-period return metrics are ROE 6.6%, ROA 3%, ROCE 10.2%. Low capital returns limit the ability to compound value internally.
The PEG ratio is 3.01x; investors pay a high price per unit of expected growth.
The cash cycle lengthened by 22.7 days to 109.6 days. Operations require more funding.
Overall assessment
Becton, Dickinson and Company's multiples look low against history, but fundamental returns do not yet provide convincing support.
Annual Financial Ratios Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
33.5 | 37.6 | 45.6 | 37.7 | 34.2 | 79.8 | 56.0 | 191.6 | 41.5 | 36.6 | 41.5 | 20.8 | 15.9 | 13.2 | 13.9 | 9.6 | 10.2 | 14.0 | - | - |
P/S |
2.6 | 3.2 | 3.5 | 3.6 | 3.7 | 4.3 | 4.0 | 3.7 | 3.8 | 2.9 | 2.8 | 2.9 | 2.6 | 2.0 | 2.2 | - | - | - | - | - |
EPS |
5.8 | 5.9 | 5.0 | 5.9 | 6.9 | 2.8 | 4.0 | 0.6 | 4.7 | 4.6 | 3.4 | 6.1 | 6.6 | 5.7 | 5.8 | 5.6 | 5.1 | 4.6 | 3.6 | - |
EV (Enterprise Value) |
55.5 B | 62.4 B | 66.2 B | 66.1 B | 69.1 B | 66.8 B | 99.2 B | 91.3 B | 56.3 B | 52.1 B | 47.1 B | 30.2 B | 25.8 B | 21 B | 22 B | 11.5 B | 11.1 B | 14.9 B | -511 M | -1 B |
EBITDA per Share |
17.5 | 16.2 | 15.4 | 15.8 | 15.5 | 10.8 | 16.6 | 16.3 | 13.3 | 15.4 | 11.8 | 11.2 | 9.23 | 10.1 | 10.3 | 8.85 | 8.54 | 8.02 | - | - |
EV/EBITDA |
11.0 | 13.3 | 15.0 | 14.7 | 13.6 | 20.1 | 19.6 | 18.9 | 17.2 | 14.0 | 16.8 | 12.3 | 12.6 | 8.7 | 8.4 | 5.5 | 5.4 | 7.6 | -0.3 | - |
PEG |
3.01 | 15.15 | 24.9 | 5.48 | 8.99 | 61.08 | 0.1 | -2.21 | 17.33 | 1.08 | -0.94 | -2.76 | 0.97 | -13.63 | 5.99 | - | - | - | - | - |
P/B |
1.0 | 1.1 | 1.3 | 1.3 | 1.3 | 1.3 | 3.3 | 2.8 | 3.5 | 4.7 | 4.0 | 4.9 | 4.1 | 3.7 | 3.6 | 1.3 | 1.3 | 2.0 | - | - |
P/CF |
- | - | - | - | - | - | 29.1 | 30.2 | 25.1 | 19.4 | 26.3 | 22.6 | 22.4 | 12.8 | 15.9 | - | - | - | - | - |
ROE % |
6.61 | 6.59 | 5.75 | 7.04 | 8.84 | 3.68 | 5.85 | 1.48 | 8.50 | 12.78 | 9.70 | 23.45 | 25.64 | 28.29 | 26.32 | 24.24 | 23.95 | 22.83 | - | - |
ROA % |
3.03 | 2.98 | 2.81 | 3.36 | 3.88 | 1.62 | 2.38 | 0.58 | 2.92 | 3.81 | 2.59 | 9.52 | 10.64 | 10.30 | 12.19 | 13.65 | 13.24 | 14.24 | - | - |
ROCE % |
10.16 | 9.26 | 8.18 | 9.03 | 9.50 | 3.84 | 4.85 | 4.80 | 5.33 | 10.19 | 6.69 | 15.73 | 12.53 | 16.60 | 20.49 | 29.12 | 30.91 | 30.15 | - | - |
Current Ratio |
- | - | - | - | - | - | 1.2 | 1.0 | 5.6 | 1.4 | 1.4 | 2.7 | 2.8 | 2.7 | 2.6 | - | - | - | - | - |
DSO |
50.4 | 50.4 | 44.5 | 43.9 | 45.3 | 53.9 | 49.5 | 53.0 | 52.6 | 47.3 | 57.4 | 51.3 | 56.2 | 59.2 | 57.3 | - | - | - | - | - |
DIO |
118.5 | 117.5 | 105.8 | 104.8 | 95.4 | 104.7 | 104.6 | 102.6 | 107.9 | 96.6 | 128.0 | 131.6 | 131.8 | 120.6 | 121.6 | 122.5 | 123.3 | 58.7 | - | - |
DPO |
59.3 | 58.4 | 54.4 | 60.4 | 53.8 | 48.1 | 44.3 | 46.3 | 47.3 | 37.4 | 41.2 | 35.3 | 31.3 | 34.1 | 29.8 | 31.4 | 28.9 | 14.2 | - | - |
Operating Cycle |
168.9 | 167.8 | 150.4 | 148.7 | 140.7 | 158.6 | 154.1 | 155.5 | 160.5 | 144.0 | 185.4 | 182.9 | 188.0 | 179.8 | 178.9 | 122.5 | 123.3 | 58.7 | - | - |
Cash Conversion Cycle |
109.6 | 109.4 | 96.0 | 88.3 | 86.9 | 110.4 | 109.8 | 109.3 | 113.2 | 106.6 | 144.2 | 147.6 | 156.7 | 145.7 | 149.1 | 91.2 | 94.3 | 44.5 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Becton, Dickinson and Company
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.37 | -1.11 | 1.34 | 1.34 | 2 | 2 | 1.07 | 1.05 | 1.68 | 1.68 | 1.85 | 0.97 | 1.37 | 1.37 | 1.54 | 1.71 | - | 1.18 | 1.51 | 2.3 | - | 1.73 | 0.95 | 3.38 | 0.36 | 0.98 | 3.38 | 0.88 | 0.46 | 1.53 | 0.88 | 2.09 | -0.64 | 2.08 | 2.09 | -0.76 | 1.27 | -0.75 | -0.76 | 2.64 | 0.09 | 1.83 | 2.64 | 1.08 | 0.86 | 0.3 | 1.08 | 1.22 | 1.56 | 1.69 | 1.22 | 1.4 | 6.16 | 1.55 | 1.4 | 3.18 | 4.24 | 1.62 | 3.18 | 1.23 | 4.36 | 1.57 | 1.23 | 1.32 | 1.26 | 1.33 | 1.42 |
EBITDA per Share |
4.47 | 2.34 | 4.08 | 4.08 | 9.45 | 4.45 | 3.28 | 3.66 | 7.95 | 3.33 | 3.8 | 3.45 | 7.86 | 3.2 | 3.5 | 4.06 | - | 3.13 | 3.21 | 4.35 | - | 6.01 | 2.69 | 6.18 | 10.3 | 5.05 | 6.18 | 3.8 | 12.4 | 6.48 | 3.8 | 5.39 | 9.2 | 5.06 | 5.39 | 2.29 | 8.51 | 1.36 | 2.26 | 5.04 | 10.2 | 5.09 | 5.04 | 3.03 | 6.79 | 1.97 | 3.03 | 2.53 | 8.35 | 3.71 | 2.53 | 2.68 | 8.1 | 3.44 | 2.68 | 2.65 | 7.48 | 3.51 | 2.65 | 2.19 | 3.99 | 0.92 | 2.31 | 3.53 | - | - | - |
ROE % |
3.28 | 3.99 | 7.53 | 7.24 | 6.93 | 6.56 | 6.19 | 7.06 | 6.97 | 6.65 | 6.34 | 6.04 | 6.93 | 7.21 | 8.44 | 8.83 | 6.83 | 6.83 | 8.09 | 10.31 | 7.50 | 8.04 | 7.07 | 10.03 | 7.27 | 7.51 | 8.44 | 5.54 | 7.03 | 5.61 | 6.30 | 7.84 | 4.40 | 7.57 | 3.72 | -0.18 | 7.87 | 5.59 | 11.72 | 20.13 | 15.89 | 18.17 | 13.93 | 9.76 | 11.25 | 14.68 | 20.26 | 21.74 | 22.42 | 40.31 | 39.85 | 40.65 | 49.30 | 46.74 | 48.66 | 58.31 | 49.89 | 48.70 | 47.90 | 38.23 | 38.62 | 24.29 | 23.20 | 24.29 | 5.78 | 6.01 | 6.54 |
ROA % |
1.52 | 1.83 | 3.48 | 3.35 | 3.21 | 3.04 | 2.87 | 3.30 | 3.28 | 3.17 | 3.06 | 2.92 | 3.34 | 3.40 | 3.90 | 4.02 | 3.06 | 3.06 | 3.62 | 4.62 | 3.35 | 3.59 | 3.15 | 4.46 | 3.16 | 3.24 | 3.58 | 2.26 | 2.85 | 2.29 | 2.52 | 3.09 | 1.72 | 2.83 | 1.38 | -0.09 | 2.47 | 1.68 | 3.55 | 6.11 | 4.67 | 5.28 | 3.99 | 2.66 | 3.06 | 4.81 | 7.19 | 8.22 | 9.20 | 16.67 | 16.54 | 16.91 | 20.03 | 17.89 | 18.28 | 21.51 | 18.44 | 20.00 | 20.41 | 17.42 | 18.52 | 12.54 | 12.73 | 14.06 | 3.33 | 3.48 | 3.85 |
ROCE % |
7.47 | 8.21 | 11.29 | 11.27 | 10.89 | 9.75 | 8.61 | 9.31 | 9.25 | 9.04 | 8.83 | 8.41 | 8.97 | 9.16 | 9.91 | 10.06 | 7.77 | 7.77 | 9.60 | 12.33 | 9.47 | 14.64 | 13.54 | 16.93 | 14.26 | 16.91 | 18.38 | 15.53 | 17.32 | 13.94 | 13.41 | 15.26 | 12.22 | 15.77 | 11.61 | 9.15 | 18.74 | 28.23 | 36.71 | 45.56 | 39.74 | 33.13 | 28.28 | 22.57 | 24.59 | 37.54 | 44.43 | 46.43 | 46.98 | 46.52 | 45.74 | 46.33 | 47.66 | 52.56 | 55.39 | 57.37 | 55.73 | 53.41 | 51.81 | 49.76 | 51.18 | 33.59 | 32.80 | 33.66 | 8.36 | 8.48 | 8.28 |
DSO |
41.8 | 45.6 | 43.6 | 47.4 | 48.8 | 49.5 | 49.0 | 46.2 | 47.5 | 47.1 | 43.6 | 45.4 | 45.2 | 45.1 | 44.4 | 44.5 | - | 22.6 | 43.0 | 45.2 | - | 42.7 | 45.2 | 40.9 | 45.7 | 56.8 | 38.4 | 47.7 | 46.7 | 49.2 | 49.2 | 49.7 | 48.1 | 49.5 | 46.7 | 55.5 | 50.3 | 52.4 | 50.1 | 49.0 | 45.7 | 45.5 | 48.2 | 47.8 | 48.7 | 47.7 | 40.5 | 49.3 | 49.2 | 50.2 | 51.2 | 53.3 | 19.0 | 55.1 | 54.5 | 58.0 | 19.9 | 57.6 | 57.4 | 59.0 | 20.0 | 57.4 | 29.7 | - | - | - | - |
DIO |
114.1 | 132.6 | 131.2 | 129.0 | 125.3 | 121.8 | 114.8 | 110.7 | 110.7 | 110.3 | 108.7 | 117.4 | 117.9 | 119.0 | 128.1 | 127.0 | - | 57.8 | 108.9 | 107.8 | - | 97.2 | 97.4 | 98.2 | 36.0 | 114.0 | 97.2 | 108.4 | 35.2 | 103.4 | 103.6 | 103.8 | 34.9 | 98.9 | 113.0 | 143.0 | 36.5 | 108.3 | 104.7 | 105.9 | 32.6 | 95.0 | 115.0 | 114.0 | 45.2 | 91.9 | 100.4 | 136.4 | 44.8 | 130.4 | 134.3 | 133.6 | 44.6 | 128.8 | 128.6 | 132.7 | 40.6 | 119.5 | 127.7 | 127.0 | 42.8 | 123.1 | 116.6 | 115.2 | 119.9 | 117.6 | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.8 | - | - | - | 23.9 | 8.9 | - | - | 22.2 | 7.5 | - | - | 23.1 | 7.9 | - | - | 23.8 | 8.0 | - | - | 20.6 | 6.3 | - | - | 18.2 | 7.3 | - | - | 18.2 | 6.0 | - | - | 15.5 | 5.3 | - | - | 17.9 | 5.7 | - | - | 15.4 | 5.2 | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 176.4 | - | 171.2 | 163.8 | 156.9 | - | 157.4 | 152.4 | 162.8 | - | 164.1 | 172.5 | 171.5 | - | 80.4 | 151.9 | 153.0 | - | 139.9 | 142.6 | 139.1 | 81.7 | 170.8 | 135.6 | 156.1 | 81.9 | 152.6 | 152.8 | 153.5 | 83.0 | 148.3 | 159.7 | 198.4 | 86.8 | 160.7 | 154.8 | 154.8 | 78.3 | 140.6 | 163.2 | 161.9 | 93.8 | 139.6 | 140.8 | 185.7 | 94.0 | 180.6 | 185.5 | 186.8 | 63.6 | 183.9 | 183.1 | 190.8 | 60.5 | 177.1 | 185.1 | 186.0 | 62.8 | 180.6 | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | 176.4 | - | 171.2 | 163.8 | 156.9 | - | 157.4 | 152.4 | 162.8 | - | 164.1 | 172.5 | 171.5 | - | 80.4 | 151.9 | 120.2 | - | 139.9 | 142.6 | 115.2 | 72.8 | 170.8 | 135.6 | 134.0 | 74.4 | 152.6 | 152.8 | 130.4 | 75.1 | 148.3 | 159.7 | 174.6 | 78.8 | 160.7 | 154.8 | 134.2 | 72.0 | 140.6 | 163.2 | 143.6 | 86.6 | 139.6 | 140.8 | 167.5 | 88.0 | 180.6 | 185.5 | 171.3 | 58.3 | 183.9 | 183.1 | 172.9 | 54.7 | 177.1 | 185.1 | 170.5 | 57.6 | 180.6 | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Becton, Dickinson and Company, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
$ 54.3 | 0.02 % | $ 10.8 B |  USA |
 |
electroCore
ECOR
|
$ 9.51 | 0.31 % | $ 80.7 K | USA |
 |
Glaukos Corporation
GKOS
|
$ 161.29 | 0.1 % | $ 9.22 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 119.47 | 17.38 % | $ 5.64 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.13 | 0.12 % | $ 361 M | USA |
 |
ICU Medical
ICUI
|
$ 157.18 | 0.74 % | $ 3.87 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 13.41 | 0.6 % | $ 277 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 102.6 | 0.52 % | $ 3.28 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 415.41 | 0.21 % | $ 148 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.0 | 0.67 % | $ 139 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 79.64 | 0.42 % | $ 1.8 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.07 | 4.67 % | $ 49 M |  Israel |
 |
Milestone Scientific
MLSS
|
$ 0.36 | 0.03 % | $ 29.5 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 85.25 | 0.19 % | $ 5.04 B | USA |
 |
Nephros
NEPH
|
$ 3.29 | 2.81 % | $ 34.9 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 22.72 | 0.06 % | $ 3.82 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.8 | 1.74 % | $ 279 M | USA |
 |
Pro-Dex
PDEX
|
$ 62.21 | 1.08 % | $ 201 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 49.98 | 1.81 % | $ 3.37 B | USA |
 |
Repligen Corporation
RGEN
|
$ 163.84 | 1.93 % | $ 9.21 M | USA |
 |
ResMed
RMD
|
$ 226.73 | 0.33 % | $ 33 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.66 | 1.94 % | $ 19.8 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 22.38 | 0.09 % | $ 1.11 B | USA |
 |
STERIS plc
STE
|
$ 210.76 | 0.52 % | $ 20.7 B | USA |
 |
Stereotaxis
STXS
|
$ 1.11 | 0.42 % | $ 101 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 124.19 | 0.18 % | $ 5.54 B | USA |
 |
Utah Medical Products
UTMD
|
$ 73.88 | 0.58 % | $ 239 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 363.27 | 0.03 % | $ 26.3 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 8.69 | 1.76 % | $ 1.73 B | USA |
 |
AngioDynamics
ANGO
|
$ 11.23 | 2.85 % | $ 466 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B | USA |
 |
Alcon
ALC
|
$ 63.13 | 0.17 % | $ 31.1 B |  Schweiz |
 |
AtriCure
ATRC
|
$ 52.84 | 0.11 % | $ 2.52 B | USA |
 |
Baxter International
BAX
|
$ 23.9 | 0.58 % | $ 12.3 B | USA |